$APDN
APPLIED DNA SCIENCES INC

2023 Q1 Form 10-Q Financial Statement

#000141057823000091 Filed on February 09, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4
Revenue $4.408M $5.263M
YoY Change -28.3% 26.34%
Cost Of Revenue $2.600M $2.885M
YoY Change -28.93% -5.61%
Gross Profit $1.807M $2.378M
YoY Change -27.37% 114.37%
Gross Profit Margin 41.01% 45.18%
Selling, General & Admin $3.523M $2.625M
YoY Change 3.22% -43.69%
% of Gross Profit 194.9% 110.42%
Research & Development $988.7K $971.3K
YoY Change -7.6% -10.07%
% of Gross Profit 54.7% 40.85%
Depreciation & Amortization $344.5K $338.9K
YoY Change 7.36% 5.66%
% of Gross Profit 19.06% 14.25%
Operating Expenses $4.511M $3.597M
YoY Change 0.64% -37.37%
Operating Profit -$2.704M -$1.219M
YoY Change 35.59% -73.69%
Interest Expense $3.640K $3.690K
YoY Change -34.3% 1266.67%
% of Operating Profit
Other Income/Expense, Net $661.00 $8.846K
YoY Change -100.41% -110.05%
Pretax Income $551.2K -$3.844M
YoY Change -131.32% -18.57%
Income Tax $0.00 $0.00
% Of Pretax Income 0.0%
Net Earnings $588.3K -$3.843M
YoY Change -133.45% -18.59%
Net Earnings / Revenue 13.35% -73.03%
Basic Earnings Per Share $0.05 -$0.30
Diluted Earnings Per Share $0.05 -$0.30
COMMON SHARES
Basic Shares Outstanding 12.91M 12.91M
Diluted Shares Outstanding 12.91M 12.91M

Balance Sheet

Concept 2023 Q1 2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $12.29M $12.88M
YoY Change 88.66% 368.54%
Cash & Equivalents $12.29M $12.88M
Short-Term Investments
Other Short-Term Assets $758.5K $924.7K
YoY Change 17.79% 55.89%
Inventory $366.1K $477.0K
Prepaid Expenses
Receivables $1.968M $4.053M
Other Receivables $0.00 $0.00
Total Short-Term Assets $15.38M $18.33M
YoY Change 37.87% 115.69%
LONG-TERM ASSETS
Property, Plant & Equipment $1.575M $1.866M
YoY Change -40.07% -33.55%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $750.0K $98.99K
YoY Change 689.31% 4.16%
Total Long-Term Assets $3.796M $1.965M
YoY Change 39.37% -32.32%
TOTAL ASSETS
Total Short-Term Assets $15.38M $18.33M
Total Long-Term Assets $3.796M $1.965M
Total Assets $19.18M $20.30M
YoY Change 38.16% 78.01%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.647M $2.023M
YoY Change 14.61% 14.92%
Accrued Expenses $1.725M $1.033M
YoY Change -4.3% 35.78%
Deferred Revenue $283.3K $273.9K
YoY Change -28.03% -40.14%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.655M $3.330M
YoY Change 0.61% 11.79%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $5.552M $7.809M
YoY Change 113.59% 24713.06%
Total Long-Term Liabilities $5.552M $7.809M
YoY Change 113.59% 24713.06%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.655M $3.330M
Total Long-Term Liabilities $5.552M $7.809M
Total Liabilities $9.207M $11.14M
YoY Change 47.72% 270.01%
SHAREHOLDERS EQUITY
Retained Earnings -$295.8M -$296.3M
YoY Change 1.73% 2.6%
Common Stock $305.8M $305.5M
YoY Change 2.48% 2.78%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $10.01M $9.162M
YoY Change
Total Liabilities & Shareholders Equity $19.18M $20.30M
YoY Change 38.16% 78.01%

Cashflow Statement

Concept 2023 Q1 2022 Q4
OPERATING ACTIVITIES
Net Income $588.3K -$3.843M
YoY Change -133.45% -18.59%
Depreciation, Depletion And Amortization $344.5K $338.9K
YoY Change 7.36% 5.66%
Cash From Operating Activities $214.4K -$2.383M
YoY Change -181.86% -35.62%
INVESTING ACTIVITIES
Capital Expenditures $54.34K $0.00
YoY Change -182.92% -100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $45.00K
YoY Change
Cash From Investing Activities -$54.34K $45.00K
YoY Change -17.08% -142.99%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities 214.4K -2.383M
Cash From Investing Activities -54.34K 45.00K
Cash From Financing Activities 0.000
Net Change In Cash 160.0K -2.338M
YoY Change -95.75% -38.58%
FREE CASH FLOW
Cash From Operating Activities $214.4K -$2.383M
Capital Expenditures $54.34K $0.00
Free Cash Flow $160.0K -$2.383M
YoY Change -181.51% -37.4%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q4 apdn Base Rent
BaseRent
6500
CY2022Q4 us-gaap Short Term Lease Commitment Amount
ShortTermLeaseCommitmentAmount
50839
CY2022Q4 us-gaap Operating Lease Expense
OperatingLeaseExpense
148826
CY2021Q4 us-gaap Operating Lease Expense
OperatingLeaseExpense
142952
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
40831
CY2022Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
330853
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
924682
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1058056
CY2022Q4 us-gaap Gross Profit
GrossProfit
2377683
CY2021Q4 us-gaap Gross Profit
GrossProfit
1109138
CY2022Q4 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2625357
CY2021Q4 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
4735619
CY2022Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
971304
CY2021Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1080096
CY2022Q4 us-gaap Operating Expenses
OperatingExpenses
3596661
CY2021Q4 us-gaap Operating Expenses
OperatingExpenses
5815715
CY2021Q4 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
273
CY2022Q4 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
2637800
CY2021Q4 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0
CY2022Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
8846
CY2021Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-14607
CY2022Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12908520
CY2021Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7486120
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 dei Entity Central Index Key
EntityCentralIndexKey
0000744452
CY2022Q4 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--09-30
CY2022Q4 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2022Q4 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q4 dei Amendment Flag
AmendmentFlag
false
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12908520
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12908520
CY2022Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.30
CY2021Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.48
CY2022Q4 apdn Fair Value Assets Level2 To Level1 Transfers Amount1
FairValueAssetsLevel2ToLevel1TransfersAmount1
0
CY2022Q4 apdn Fair Value Liabilities Level2 To Level1 Transfers Amount1
FairValueLiabilitiesLevel2ToLevel1TransfersAmount1
0
CY2022Q4 apdn Fair Value Liabilities Level1 To Level2 Transfers Amount1
FairValueLiabilitiesLevel1ToLevel2TransfersAmount1
0
CY2022Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2022Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2022Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2022Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2022Q4 us-gaap Fair Value Recurring Basis Unobservable Input Reconciliation Liability Gain Loss Statement Of Income Extensible List
FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList
http://fasb.org/us-gaap/2022#FairValueAdjustmentOfWarrants
CY2022Q4 dei Document Type
DocumentType
10-Q
CY2022Q4 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q4 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022Q4 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q4 dei Entity File Number
EntityFileNumber
001-36745
CY2022Q4 dei Entity Registrant Name
EntityRegistrantName
Applied DNA Sciences, Inc.
CY2022Q4 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q4 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
59-2262718
CY2022Q4 dei Entity Address Address Line1
EntityAddressAddressLine1
50 Health Sciences Drive
CY2022Q4 dei Entity Address City Or Town
EntityAddressCityOrTown
Stony Brook
CY2022Q4 dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
CY2022Q4 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
11790
CY2022Q4 dei City Area Code
CityAreaCode
631
CY2022Q4 dei Local Phone Number
LocalPhoneNumber
240-8800
CY2022Q4 dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
CY2022Q4 dei Trading Symbol
TradingSymbol
APDN
CY2022Q4 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q4 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q4 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q4 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022Q4 dei Entity Small Business
EntitySmallBusiness
true
CY2022Q4 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021Q4 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
855
CY2022Q4 dei Entity Shell Company
EntityShellCompany
false
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
12908520
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12877179
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15215285
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
4053477
CY2022Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3067544
CY2022Q4 us-gaap Inventory Net
InventoryNet
477014
CY2022Q3 us-gaap Inventory Net
InventoryNet
602244
CY2022Q4 us-gaap Income Taxes Paid
IncomeTaxesPaid
0
CY2022Q4 us-gaap Assets Current
AssetsCurrent
18332352
CY2022Q3 us-gaap Assets Current
AssetsCurrent
19943129
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1865772
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2222988
CY2022Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
98987
CY2022Q3 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
98997
CY2022Q4 us-gaap Assets
Assets
20297111
CY2022Q3 us-gaap Assets
Assets
22265114
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3056123
CY2022Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3621751
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
273880
CY2022Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
563557
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3330003
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
4185308
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Noncurrent
AccountsPayableAndAccruedLiabilitiesNoncurrent
31467
CY2022Q3 us-gaap Accounts Payable And Accrued Liabilities Noncurrent
AccountsPayableAndAccruedLiabilitiesNoncurrent
31467
CY2022Q4 apdn Common Warrant Liability Noncurrent
CommonWarrantLiabilityNoncurrent
7777200
CY2022Q3 apdn Common Warrant Liability Noncurrent
CommonWarrantLiabilityNoncurrent
5139400
CY2022Q4 us-gaap Liabilities
Liabilities
11138670
CY2022Q3 us-gaap Liabilities
Liabilities
9356175
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12908520
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12908520
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
12909
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
12909
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
305492756
CY2022Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
305399008
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-296343460
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-292500088
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
9162205
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
12911829
CY2022Q4 us-gaap Minority Interest
MinorityInterest
-3764
CY2022Q3 us-gaap Minority Interest
MinorityInterest
-2890
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
9158441
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
12908939
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
20297111
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
22265114
CY2021Q4 us-gaap Income Taxes Paid
IncomeTaxesPaid
0
CY2022Q4 apdn Property Plant And Equipment Acquired And Included In Accounts Payable
PropertyPlantAndEquipmentAcquiredAndIncludedInAccountsPayable
20619
CY2022Q4 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
5262752
CY2021Q4 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
4165706
CY2022Q4 us-gaap Cost Of Revenue
CostOfRevenue
2885069
CY2021Q4 us-gaap Cost Of Revenue
CostOfRevenue
3056568
CY2022Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-1218978
CY2021Q4 apdn Property Plant And Equipment Acquired And Included In Accounts Payable
PropertyPlantAndEquipmentAcquiredAndIncludedInAccountsPayable
0
CY2021Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-4706577
CY2022Q4 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
3686
CY2022Q4 apdn Issuance Of Stock Options Issued For Payment Of Accrued Bonus
IssuanceOfStockOptionsIssuedForPaymentOfAccruedBonus
0
CY2022Q4 us-gaap Profit Loss
ProfitLoss
-3844246
CY2021Q4 us-gaap Profit Loss
ProfitLoss
-4720911
CY2022Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3844246
CY2021Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4720911
CY2022Q4 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-874
CY2021Q4 apdn Issuance Of Stock Options Issued For Payment Of Accrued Bonus
IssuanceOfStockOptionsIssuedForPaymentOfAccruedBonus
300000
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-3843372
CY2021Q4 us-gaap Net Income Loss
NetIncomeLoss
-4721766
CY2022Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.30
CY2021Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.63
CY2022Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12908520
CY2021Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7486120
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
12908939
CY2022Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
93748
CY2022Q4 us-gaap Profit Loss
ProfitLoss
-3844246
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
9158441
CY2021Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
11112946
CY2021Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1699920
CY2021Q4 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
300000
CY2021Q4 us-gaap Profit Loss
ProfitLoss
-4720911
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
8391955
CY2022Q4 us-gaap Profit Loss
ProfitLoss
-3844246
CY2021Q4 us-gaap Profit Loss
ProfitLoss
-4720911
CY2022Q4 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
338918
CY2021Q4 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
320751
CY2022Q4 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
6083
CY2021Q4 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0
CY2022Q4 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
2637800
CY2021Q4 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0
CY2022Q4 us-gaap Share Based Compensation
ShareBasedCompensation
93748
CY2021Q4 us-gaap Share Based Compensation
ShareBasedCompensation
1699920
CY2022Q4 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-290022
CY2021Q4 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
10000
CY2022Q4 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
695912
CY2021Q4 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1063237
CY2022Q4 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-125230
CY2021Q4 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-69304
CY2022Q4 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-133374
CY2021Q4 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
24268
CY2022Q4 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-586236
CY2021Q4 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-169991
CY2022Q4 apdn Increase Decrease In Deferred Revenues
IncreaseDecreaseInDeferredRevenues
-289677
CY2021Q4 apdn Increase Decrease In Deferred Revenues
IncreaseDecreaseInDeferredRevenues
176538
CY2022Q4 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2383106
CY2021Q4 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3701894
CY2022Q4 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
45000
CY2021Q4 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
CY2022Q4 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0
CY2021Q4 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
104686
CY2022Q4 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
45000
CY2021Q4 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-104686
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2338106
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3806580
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15215285
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6554948
CY2021Q4 us-gaap Interest Paid Net
InterestPaidNet
0
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12877179
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2748368
CY2022Q4 us-gaap Interest Paid Net
InterestPaidNet
0
CY2022Q4 apdn Number Of Primary Markets That Use Company S Technologies
NumberOfPrimaryMarketsThatUseCompanySTechnologies
3
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-296343460
CY2022Q4 us-gaap Profit Loss
ProfitLoss
-3844246
CY2022Q4 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-2383106
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12877179
CY2022Q4 apdn Working Capital Surplus Deficit
WorkingCapitalSurplusDeficit
15002349
CY2022Q4 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Management bases its estimates on historical experience and on various assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. The most significant estimates include revenue recognition, recoverability of long-lived assets, including the values assigned to property and equipment, fair value calculations for warrants, contingencies, and management’s anticipated liquidity. Management reviews its estimates on a regular basis and the effects of any material revisions are reflected in the consolidated financial statements in the period they are deemed necessary. Accordingly, actual results could differ from those estimates. </p>
CY2022Q4 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
5262752
CY2021Q4 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
4165706
CY2022Q4 us-gaap Contract With Customer Liability Increase Decrease For Contract Acquired In Business Combination
ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination
289677
CY2022Q4 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
341285
CY2020Q4 apdn Base Rent During Initial Lease Term
BaseRentDuringInitialLeaseTerm
589056
CY2022Q4 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8301729
CY2021Q4 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1805023
CY2022Q4 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Concentrations</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash, cash equivalents and trade receivables. The Company places its cash and cash equivalents with high credit quality institutions. At times, such investments may be in excess of the FDIC insurance limit. As of December 31, 2022, the Company had cash and cash equivalents of approximately $12.2 million in excess of the FDIC insurance limit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company’s revenues earned from sale of products and services for the three-month period ended December 31, 2022 included an aggregate of 83% from two customers within the MDx Testing Services segment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">One customer from within the MDx Testing Services segment accounted for 48% of the Company’s revenues earned from sale of products and services for the three-month period ended December 31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">One customer accounted for 88% of the Company’s accounts receivable at December 31, 2022 and two customers accounted for 89% of the Company’s accounts receivable at September 30, 2022.</p>
CY2022Q4 us-gaap Time Deposits At Or Above Fdic Insurance Limit
TimeDepositsAtOrAboveFDICInsuranceLimit
12200000
CY2022Q4 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
3
CY2022Q4 apdn Fair Value Assets Level1 To Level2 Transfers Amount1
FairValueAssetsLevel1ToLevel2TransfersAmount1
0
CY2022Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
366116
CY2022Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
471947
CY2022Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
35786
CY2022Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
55817
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
75112
CY2022Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
74480
CY2022Q4 us-gaap Inventory Net
InventoryNet
477014
CY2022Q3 us-gaap Inventory Net
InventoryNet
602244
CY2017Q4 apdn Lease For Satellite Testing
LeaseForSatelliteTesting
1108
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2023295
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1744105
CY2022Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
830986
CY2022Q3 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
1458661
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
201842
CY2022Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
418985
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3056123
CY2022Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3621751
CY2022Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
7313963
CY2022Q3 apdn Weighted Average Price Per Share Warrant Outstanding
WeightedAveragePricePerShareWarrantOutstanding
3.68
CY2022Q4 apdn Class Of Warrant Or Right Forfeitures And Expirations
ClassOfWarrantOrRightForfeituresAndExpirations
18375
CY2022Q4 apdn Weighted Average Price Per Share Warrant Cancelled Or Expired
WeightedAveragePricePerShareWarrantCancelledOrExpired
17.60
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
7295588
CY2022Q4 apdn Weighted Average Price Per Share Warrant Outstanding
WeightedAveragePricePerShareWarrantOutstanding
3.65
CY2013Q2 apdn Area Of Property Under Operating Lease
AreaOfPropertyUnderOperatingLease
30000
CY2013Q2 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P3Y
CY2013Q2 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P3Y
CY2013Q2 apdn Area Of Laboratory Space
AreaOfLaboratorySpace
2200
CY2020Q1 us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
January 20, 2020
CY2020Q1 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P1Y
CY2020Q4 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P1Y
CY2017Q4 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P3Y
CY2022Q4 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
3
CY2022Q4 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
5262752
CY2022Q4 us-gaap Gross Profit
GrossProfit
2377683
CY2021Q4 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
4165706
CY2021Q4 us-gaap Gross Profit
GrossProfit
1109138
CY2022Q4 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
3686
CY2021Q4 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
273
CY2022Q4 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
2637800
CY2022Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
8846
CY2021Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-14607
CY2022Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3844246
CY2021Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4720911

Files In Submission

Name View Source Status
0001410578-23-000091-index-headers.html Edgar Link pending
0001410578-23-000091-index.html Edgar Link pending
0001410578-23-000091.txt Edgar Link pending
0001410578-23-000091-xbrl.zip Edgar Link pending
apdn-20221231.xsd Edgar Link pending
apdn-20221231x10q.htm Edgar Link pending
apdn-20221231xex31d1.htm Edgar Link pending
apdn-20221231xex31d2.htm Edgar Link pending
apdn-20221231xex32d1.htm Edgar Link pending
apdn-20221231xex32d2.htm Edgar Link pending
apdn-20221231_cal.xml Edgar Link unprocessable
apdn-20221231x10q_htm.xml Edgar Link completed
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
apdn-20221231_def.xml Edgar Link unprocessable
apdn-20221231_lab.xml Edgar Link unprocessable
apdn-20221231_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable